Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3958 | Tested for SARS-CoV-2 (regardless of the result) Wiki | 1.00 |
| drug934 | Clinical diagnosis of COVID-19 by a health care professional Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is an observational study. The aim is to describe the natural history and clinical evolution over time of hospitalized patients affected by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) infection, including the genetic pathology of the disease and improve therapeutic procedures.
Description: Description over time of hospitalized patients suffering from SARS-COV-2 infection to better understand the pathogenesis of the disease and improve the controls and therapeutic procedures.
Measure: Covid19 infection clinical evolution Time: Until patient discharge from the hospital (approximately 1 year)Description: Identify risk factors for intra-hospital mortality in hospital wards COVID + patients.
Measure: Risk factors for intra-hospital mortality Time: Until patient discharge from the hospital (approximately 1 year)Description: Assess the impact of a fragility index (IF) on the clinical course of COVID + patients.
Measure: The impact of a fragility index (IF) Time: Until patient discharge from the hospital (approximately 1 year)Description: Build a prognostic score through which it is possible define a stratification that orients, according to the state of hospitalization, the therapeutic choices.
Measure: Prognostic score Time: Until patient discharge from the hospital (approximately 1 year).Description: Differentiate the lung sequelae related to the evolution of viral damage from those of cheater / volutrauma connected to non-invasive (NIV-CPAP) or invasive (MV) ventilation methods.
Measure: The lung sequelae of SARS-COV-2 pneumonia Time: Until patient discharge from the hospital (approximately 1 year)Description: Assess the accuracy of IF in elderly patients in terms of clinical outcomes compared to one clinical evaluation based on age and co-morbidity.
Measure: The accuracy of IF in elderly patients Time: Until patient discharge from the hospital (approximately 1 year)Description: Describe the anomalies of the coagulation system, which appear on patients affected by SARS-COV-2 pneumonia.
Measure: Coagulation system anomalies Time: Until patient discharge from the hospital (approximately 1 year)Description: Description of the impact of the prone position in terms of increased oxygenation of the patient suffering from SARS-COV-2 pneumonia as an index lung recruitment.
Measure: The impact of the prone position on the oxygenation Time: Until patient discharge from the hospital (approximately 1 year)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports